Podcasts about zepbound

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

Welcome to Ozempic Weightloss Unlocked, your source for the latest insights on Ozempic—from medical updates to its real-world impact on health and lifestyle.Ozempic, also known as semaglutide, was originally designed to help manage type 2 diabetes, but it has quickly become a leading medication for weight loss. Clinical studies highlighted by Medical News Today and Drugs.com have shown that people using Ozempic can lose between 10 and 17 percent of their body weight over about 68 weeks, with results varying based on dosage and individual response. Some individuals have reported losing as much as 30 pounds in just six months, while also seeing significant improvements in blood sugar levels, such as A1C reductions from 8.5 to 6.2, according to user reviews.But what sets Ozempic apart from other medications like metformin? While both can have modest effects on body weight, Ozempic generally leads to more substantial results. According to Drugs.com, participants in trials with Ozempic and lifestyle changes lost an average of nearly 15 to 17 percent of their weight, far exceeding the modest results commonly seen with metformin.The mechanism is fascinating—Ozempic works by imitating a hormone called GLP-1, reducing appetite and slowing digestion. Yet with such rapid and notable weight loss comes important questions about long-term health. A new study from the University of Virginia, as reported by Science Daily, warns that while GLP-1 drugs like Ozempic deliver dramatic fat loss, they do not appear to improve crucial measures of cardiorespiratory fitness. Moreover, muscle loss is a real concern. Researchers have documented reductions in lean mass when using Ozempic for substantial weight loss, which could impact strength, posture, and even risk of heart problems. To counter this, doctors increasingly recommend combining Ozempic with exercise and a protein-rich diet to help maintain muscle and overall health.With these dramatic results, it's not surprising that Ozempic and similar GLP-1 drugs are making waves far outside strictly medical circles. Weight loss clinics nationwide are rethinking their programs to include these medications, as South County Medspa and Wellness notes, allowing many patients to expect a 10 to 15 percent reduction in body weight over several months. However, these treatments do not come cheap—monthly costs can reach several hundred dollars, leading to high rates of discontinuation as users stop due to expense or side effects, which can include nausea and digestive issues.And what happens if you stop Ozempic? As Professor Patricia Brubaker explains for McGill University, stopping the medication often results in some weight regain—a typical rebound of about 12 percent of what was lost—but most people still hold on to some of their original weight loss a year later. It's not quite the dreaded "yo-yo" effect, but it does highlight the importance of ongoing therapy or lifestyle modification for lasting results.In the realm of new developments, tirzepatide, branded as Zepbound, stands out as the only FDA-approved medication demonstrating even greater weight loss, with some participants losing up to 22 percent of their body weight. Meanwhile, the rise of so-called GLP-1 supplements online is causing concern among Harvard experts. According to Harvard T.H. Chan School of Public Health, these over-the-counter products are not regulated or proven effective, so listeners should approach them with skepticism.As the science evolves and new studies emerge almost weekly, there is a growing recognition among experts: medications like Ozempic can be powerful tools for weight loss, but to truly unlock healthier living, they should be paired with exercise, nutrition, and long-term, individualized care.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you never miss the latest updates and expert insights. This has been a Quiet Please production, for more check out quietplease dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why getting obesity medications like Wegovy or Zepbound feels sooo complicated and honestly, kinda impossible sometimes?Between high costs, confusing insurance rules, and endless paperwork, even patients who qualify often struggle to actually start treatment.To help us break it all down, I'm joined by Dr. Nikita Shah, a board-certified obesity medicine physician and founder of WeightSense in Orlando, Florida. She focuses on practical, health-first weight care and also serves on the Medical Society of Central Florida board and the Obesity Pillars Journal editorial board. She's all about helping patients find real-world solutions that actually work.In this episode, we cover everything you need to know about accessing obesity medications, including:Why obesity is a real medical condition, not a personal failure.How cost and insurance create the biggest hurdles.The different coverage rules for medications like Wegovy, Zepbound, and Ozempic.What prior authorization really involves—and how to get through it.Affordable medication options like Qsymia and Contrave.Why most compounded anti-obesity medications aren't the safest choice.If you're ready to finally understand the process, cut through the confusion, and learn the smartest steps to get started, listen to the full episode now!Connect with Dr. Shah:Instagram: nikitashahdoWebsite: Weight SenseBlog Mentioned: Understanding Insurance CoverageConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

When it comes to weight loss, the scale isn't the only thing that changes—your reflection and self-image often transform too. In this episode, I talk about a topic gaining attention in the media and social circles: "Ozempic face" and the emotional and physical effects of rapid weight loss, especially for those using GLP-1 medications like Wegovy, Zepbound, or Ozempic. I share a story about a friend who hesitated to increase her dosage due to concerns about skin changes, which opened the door to a larger discussion on body image during weight loss. I explain that these facial and skin changes—such as sagging, wrinkles, or looking more tired—aren't exclusive to medication use but are common with any significant weight loss, especially as we age.  Furthermore, I walk through ways to manage these concerns, like slowing down weight loss, prioritizing resistance training and protein, staying hydrated, considering aesthetic treatments, and most importantly, shifting focus from appearance to overall health. I emphasize the importance of support, tuning out unsolicited comments, and curating a healthier social media feed.  If you're navigating weight loss and struggling with body image changes like "Ozempic face," listen to this empowering episode for real talk, expert tips, and compassionate support on your journey.   Episode Highlights: What “Ozempic face” really means and why it happens Emotional impact of rapid weight loss and changing appearance How to manage body image concerns during weight loss Practical tips: strength training, hydration, and pacing weight loss Cosmetic treatment options and when to consider them The role of social media in shaping unrealistic expectations Reframing the focus from appearance to overall health and wellness Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode of the Pound of Cure Weight Loss Podcast, Dr. Matthew Weiner and registered dietitian Zoë dive deep into the latest research on GLP-1 medications and their evolving role in weight loss, muscle preservation, and even potential cancer treatment.They break down what the newest studies actually show — including why so many headlines are misleading, and how to interpret scientific research through a more critical lens.You'll also learn why strength training is non-negotiable during GLP-1 therapy or bariatric weight loss, what to know about oral semaglutide vs. injectable versions, and how nutrition plays a key role in maintaining muscle mass while losing weight.Whether you're a patient on Ozempic, Wegovy, Zepbound, or considering medication as part of your obesity treatment, this episode helps you make more informed, science-based decisions.Download our NEW FREE APP now!For Apple: https://apps.apple.com/us/app/a-pound-of-cure/id6741747271For iOS: https://play.google.com/store/apps/details?id=com.digitalbariatrics.poundofcure

VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro

It's no exaggeration to say that the past decade has revolutionized how we think about and treat obesity. Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have dominated headlines, enabling significant weight loss at speeds once considered unthinkable. The market for innovative weight loss medications is booming, with pharmaceutical companies investing heavily in hopes of developing the next blockbuster drug.However, amid this race for market dominance, many experts are questioning whether the amount of weight loss alone is the best measure of these drugs' usefulness. How can the next generation of obesity treatments meaningfully improve upon the powerful options already available?Joining The Lancet editors Callam Davidson and Miriam Sabin to discuss this question is Professor Steven Heymsfield from the Pennington Biomedical Research Center. This wide-ranging conversation covers exciting pharmaceutical advances and limitations of these treatments, including the significant disparities in access, and why these breakthroughs may have broader societal implications.Send us your feedback!Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancetCheck out all the podcasts from The Lancet Group:https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancetContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

More people than ever are turning to medicine for weight loss, but how do you know if it's right for you? In this episode, I dive into the hot topic of weight loss medications and tackle the myths, science, and facts behind them. As a board-certified obesity medicine specialist, I explain who qualifies for medications like Wegovy, Zepbound, and others, how they work, and why obesity is a chronic condition, not a personal failure. I will walk you through the medical, hormonal, and genetic factors that influence treatment, outline FDA guidelines, and share how I assess whether a patient is a good candidate. I also discuss common misconceptions, long-term use, and tips for having an informed conversation with your doctor. Because remember, It's not about shortcuts, it's about finding the right tools to improve your health and quality of life. Tune in to learn the truth about weight loss medications, debunk common myths, and find out if they're the right fit for your health journey.   Episode Highlights: Who qualifies for weight loss medications FDA-approved options Common myths debunked about weight loss drugs How GLP-1 medications work and their long-term role in obesity treatment Key factors doctors assess before prescribing Contraindications and who should not take these medications How to talk to your doctor about medical weight loss options Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are reshaping how we treat obesity — but there's so much confusion and stigma. That's why we sat down with leading obesity specialist Dr. Spencer Nadolsky for an honest, empowering conversation.We break down how GLP-1s actually work, why food noise is real, and what people aren't being told about compounded semaglutide, weight regain after bariatric surgery, and long-term success.If you've felt frustrated, misunderstood, or stuck — this episode is for you. Whether you're post-op, on medication, or considering your options, this episode brings science, support, and real talk together.

If I wanted to gain back 70 pounds, I know exactly what I'd do because I've lived it. In this episode, I'm sharing the habits, behaviors, and sneaky thought patterns that kept me stuck for years…and would absolutely pack the weight back on if I let them. From zombie eating and isolating myself to living in stretchy pants and giving in to my inner fat bitch voice, we're calling it ALL out.If you've been slipping back into these patterns or feel disconnected from yourself, this episode is your wake-up call. 

This week on Good Day Health, host Doug Stephan teams up with Dr. Ken Kronhaus to unpack the latest breakthroughs in medicine, nutrition, and public health.First up, encouraging news for women with obesity: new research suggests weight-loss medications like Ozempic and Zepbound may reduce the risk of breast cancer.Then, a fascinating look at how AI is transforming modern medicine — from designing custom proteins to combat cancer and antibiotic-resistant infections, to decoding how aging truly works.Got heartburn? Dr. Ken explains why some weight-loss drugs are causing GERD-like symptoms, how to tell if you have acid reflux, and what to do about it.Confused about gluten intolerance vs. gluten allergies? Learn how they differ — and why they're often mistakenly tied to GERD.From the gardenia fruit to your Gatorade — the FDA just approved a natural blue food dye, and we're diving into what it means for your health.COVID-19 continues to follow a seasonal pattern, according to new CDC data — but what should you actually dowith that info?Plus: Is aluminum in deodorant dangerous?And should you worry about pneumonic plague after a case surfaced in Arizona?Join Doug and Dr. Ken for trusted insights, straight talk, and smart science. Call Lake Cardiology: (352) 735-1400Website: GoodDayNetworks.comSocial Media: @GoodDayNetworks

On June 4, 2021, the FDA approved Wegovy for the treatment of chronic obesity and overweight individuals. Dr. John Sharretts, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research, said, "Today's approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program. FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight." Read the full post at http://RunningAFEVER.com/413 Photo by Pavel Danilyuk: https://www.pexels.com/photo/woman-in-white-mesh-crop-top-and-pink-bra-7653700/

TikTok claims to have banned “SkinnyTok,” but disordered eating content continues to thrive under rebranded hashtags, edited images, and wellness culture language. In this eye-opening episode of Dr. Marianne-Land, Dr. Marianne Miller is joined by eating disorder prevention advocate and educator Jen Tomei (@askjenup) to unpack the rise of SkinnyTok and its harmful influence on teens and adults alike. Jen, founder of the Jenup Community in the UK, shares firsthand experiences of discovering disturbing content on TikTok—even after reporting and flagging videos, the algorithm continued pushing them. Together, she and Dr. Marianne draw chilling parallels to the pro-ana forums of the early 2000s, and explore how new forms of tech—including AI-edited bodies—are further distorting body image online. They also examine how neurodivergent teens, who are often more vulnerable to extreme thinking and sensory overload, may be especially impacted by these trends. Plus, they critique the rise of weight loss drugs like Ozempic and their potential to normalize restriction—even in pediatric settings. WHAT YOU'LL LEARN IN THIS EPISODE: Why SkinnyTok still exists despite being technically banned How TikTok's algorithm can push disordered content—even without user interaction What “pro-ana” and “thinspo” culture looks like in 2025 The physiological damage caused by overexercise and undereating How social media is shaping disordered eating culture in schools globally The link between ADHD, cortisol, and disordered eating behaviors How weight loss drugs like Ozempic may impact teens' mental and physical health Why media literacy and early intervention in schools are urgently needed CONTENT CAUTIONS: This episode includes discussion of disordered eating, anorexia, pro-eating disorder content, social media harm, and weight loss medications including Ozempic and Zepbound. MEET OUR GUEST: Jen Tomei is the founder of Jenup.com, a UK-based organization providing school workshops on eating disorder prevention, body image, and self-esteem. A survivor of an eating disorder and a late-diagnosed ADHD adult, Jen brings both lived experience and professional insight into the complex intersection of neurodivergence, mental health, and diet culture.

With the recent approval and arrival of Zepbound in B.C this week - a powerful rival to Ozempic, and generics potentially right around the corner, it's part of a growing movement that's changing how we treat obesity as a chronic disease, and not a lifestyle failure. Guest: Dr. Akshay Jain - Endocrinologist based in Surrey, B.C Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Irresistible You podcast, we're diving into what it means to embrace your cozy or “soft life” era, without the guilt. I used to think that doing cozy things like diamond painting or relaxing at home was lazy… or worse, that stillness would lead to weight gain. I thought if it didn't make money or burn calories, it was a waste of time. But now I know better.I'm sharing how I've started doing things that pull me rather than constantly pushing myself and how that shift has helped me stop emotional eating, feel more grounded, and finally listen to my body. Cozy isn't laziness, it's restoration.If you've ever felt stuck between hustle culture and burnout, this episode is for you.

What up, Beasts. Welcome back to the show! This week on the Unveiling the Beast podcast, I sat down with Katie Sorensen, a nurse practitioner and owner of Weight Loss NP, to dig into one of the most misunderstood topics on the internet right now: GLP-1 medications. You know, the ones people love to hate, like Ozempic and ZepBound. As someone who's been waist-deep in the research for months (because yes, that's what us nerdy, weight-neutral coaches do), I wanted to bring nuance and facts into a conversation that's gotten way too loud and way too shallow. Katie broke down what these meds actually are, how they work with your body (not against it), and why calling them “the easy way out” is just lazy and harmful. Spoiler: they've been around for decades, are made of naturally occurring peptides, and they're doing a hell of a lot more than shrinking waistlines.We also talked about the emotional weight behind physical weight, the ridiculous judgment people face for using science to support their health, and how these meds are turning down the obsessive food noise that steals so much brain space. Katie and I are both on the same page: it's not about glorifying weight loss. It's about freeing people to focus on what actually matters in life. We covered everything from muscle preservation to mental health to why strength training is the real anti-aging hack. And if you've ever looked at someone using a weekly injection and thought, “Must be nice,” this episode will shift your perspective. As always, we ended with some wisdom, and Katie's was simple and powerful: get outside, soak in the sunshine, and walk. Because sometimes, the best medicine is free and found in the fresh air.As always, I hope something lands with you today. I hope something you hear tugs at your heart strings and/or I hope you laugh.Bio: Katie Sorensen, NP-C, is a passionate Nurse Practitioner dedicated to transforming lives through her innovative and holistically focused practice, Weight Loss NP, LLC. With a mission to empower individuals to achieve optimal health and vitality, Weight Loss NP specializes in personalized medical weight loss and metabolic health solutions that deliver real and lasting results.Music by Prymary: Sean Entrikin (my hot husband) on guitar, Chris Quirarte on drums, Smiley Sean on keyboards, Rob Young on bass, and Jaxon Duane on vocals.Previous Episodes about GLP-1s151 This Might Be The Most Honest GLP-1 Conversation on the Internet154 The Science of GLP-1s and Why it's Blowing My MindGLP-1 Studies I've looked at: https://storage.googleapis.com/msgsndr/AX1su0J5xvxdddMmNWzF/media/685765ea077fba411ec88ff3.pdfConnect with Katie!Website: www.theWLNP.comYouTube: www.youtube.com/@WeightLossNPFacebook: https://www.facebook.com/weightlossnpcoWhere can you find me?Linktree: https://linktr.ee/beautifulbeastwithinstudiosWhat if health wasn't about rules or restriction?What if it felt more like trust, ease, and actually liking the person in the mirror?I help people rebuild their relationship with food, movement, and themselves, so health becomes something you live, not something you chase.Ready for a different kind of conversation? Let's talk. No pressure.https://beautifulbeastwithinstudios.com/exploration-chat-schedulingAffiliate LinksBreakthrough Coaching Certification: If you feel called to help others heal or grow, Sean Smith's Breakthrough Coaching Certification is where that calling becomes real. https://coachseansmith.ontraport.net/t?orid=27037&opid=43Opus Clip: I use Opus Clip mostly for captions, and it's a game-changer for turning long videos into usable clips. If you use my link, it supports the show, and I appreciate you big time! https://www.opus.pro/?via=1118d2Mary Kay: Grab your faves here: https://www.marykay.com/kaitienoelleUnveil the Beautiful Beast Within YOU!Zoom Background:By Behr

In this episode, we dive deep into the biggest stories shaping the markets right now. Intel has officially fallen out of the top 10 semiconductor companies — is it too late for them to catch up, and which 3 chipmakers should investors focus on instead? We also break down how stock options can be used as a powerful wealth-building tool when used the right way.With Nvidia flirting with a $4 trillion valuation after an explosive 870% AI-led rally, we discuss whether it's headed for a meltdown or another breakout — and which overlooked metric might signal what's next. Bitcoin also hit a new all-time high heading into Crypto Week, and we break down what this means for the broader crypto market.Next, we analyze who the real winners and losers in Big Tech have been since Trump took office, and what it means for investors moving forward. With U.S. equity fund inflows collapsing from $31.6 billion to just $2.1 billion, we ask: are you buying the dip or parking cash on the sidelines? Lastly, we look at Eli Lilly and whether its new Zepbound pill could drive a potential 40% surge in the stock over the next year.EYLU 24 Hour 50% off Sale (Code: Marketmondays) https://eyluniversity.comInvest Fest Ticket Link: https://investfest.com#Investing #StockMarket #Crypto #Bitcoin #Nvidia #Intel #EliLilly #Zepbound #TechStocks #InvestFest #EarnYourLeisure #MarketMondays #FinancialFreedom #OptionsTradingOur Sponsors:* Check out PNC Bank: https://www.pnc.comSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Driveway Beers PodcastWeight Loss and The Yukon!!We've been saying that we'd update you on our weight loss for 3 episodes now and we failed to come through. But this week, we fullfill the promise and give an update on Mike and Alex's weight loss (or gains) since the last episode. And the saga of the 04 Yukon Denali continues. Did Alex finally get it sorted out?? Why won't he just buy a new car already?? #cars #suv #weight #loss #weightloss #health #ozempic #zepbound #drugs #conservative #liberal #GeneralMotors #autos Please subscribe and rate this podcast on your podcast platforms like Apple and Spotify as it helps us a ton. Also like, comment, subscribe and share the video on Youtube. It really helps us get the show out to more people. We hope you enjoyed your time with us and we look forward to seeing you next time. Please visit us at https://drivewaybeerspodcast.com/donate/ to join The Driveway Club and buy us a bourbon! Buy us a bottle and we'll review it on a show!Leave us a comment and join the conversation on our discord at https://discord.gg/rN25SbjUSZ.Please visit our sponsors:Adam Chubbuck of Team Alpha Charlie Real Estate, 8221 Ritchie Hwy, Pasadena, MD 21122, www.tacmd.com, (443) 457-9524. If you want a real estate agent that will treat your money like it's his own and provide you the best service as a buyer or seller, contact Adam at Team Alpha Charlie.If you want to sponsor the show, contact us at contact@drivewaybeerspodcast.comCheck out all our links here https://linktr.ee/drivewaybeerspodcast.comIf you're looking for sports betting picks, go to conncretelocks.com or send a message to Jeremy Conn at Jconn22@gmail.comFacebook Page https://www.facebook.com/drivewaybeerspodcast/#podcast #whiskey #bourbon

Did you know that stopping GLP-1 medications like Ozempic or Wegovy can trigger powerful biological and emotional changes that impact your weight journey? In this episode, I talk about what happens when you stop taking a GLP-1 medication, like Ozempic, Wegovy, or Zepbound. I explain how these medications work by slowing stomach emptying, reducing appetite, and helping with insulin regulation, which supports weight loss and benefits conditions like type 2 diabetes and PCOS. However, I also share that they're not magic pills, you still need healthy habits like eating well and exercising. I highlight possible side effects, such as nausea or pancreatitis risks, and emphasize that stopping these medications can lead to increased hunger, cravings, weight regain, and even emotional distress. But I also reassure you that this isn't a sign of failure. Weight regain is often biological, not personal. I offer tips for tapering off safely, reinforcing lifestyle habits, and exploring other options. Most importantly, I remind you that your journey is valid, you're not alone, and lasting success requires a plan, support, and self-compassion. Tune in to learn what really happens when you stop taking GLP-1 medications—and how to stay empowered and in control of your weight journey.   Episode Highlights: How GLP-1 medications like Ozempic and Wegovy work Common side effects and safety considerations What to expect when stopping GLP-1s, both physically and emotionally Strategies to manage weight regain and maintain healthy habits Alternative tools and support options beyond medication Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.Contextualizing the appetite for GLP-1s (0:46)Build, buy, acquire: How Novo Nordisk and Eli Lilly are meeting demand (04:05)The implications of Novo Nordisk's $16.5 billion Catalent acquisition (05:53)How to decide whether to acquire or outsource (07:23)Where in the world is GLP-1 manufacturing going next? (10:36)DTC, telehealth, and the future of GLP-1 channel strategy (13:16)How AI is driving pharma innovation at Novo Nordisk, Eli Lilly, Johnson & Johnson, and Merck (17:13)

Skinny Bones: An Overlooked Risk of Modern Weight Loss TreatmentIf you're considering or already using weight loss injections like Ozempic, Zepbound,  or Wegovy, this is a conversation you can't afford to miss.In under 8 minutes, this episode of Dr. Pepper...Really? will open your eyes to a little-known health concern hiding behind the weight loss hype—bone loss. Host Dr. Gary Pepper, a seasoned endocrinologist, introduces Linda, a postmenopausal woman weighing her options, to explore the deeper risks tied to rapid weight reduction.What you'll learn:Why losing weight quickly—especially after menopause—could accelerate bone thinningThe silent risk of fractures and the shocking reality of post-fracture outcomesWhy the FDA doesn't require bone safety data in weight loss drug trialsWhat simple screening and prevention steps you should be taking nowHow to protect yourself from malnutrition and bone loss with the right tools and knowledgeUnlike typical wellness advice, this podcast digs into the real science and unspoken gaps in our current weight loss culture. It's not about fear—it's about informed choices. You'll walk away with practical strategies and a new perspective on how to lose weight without losing your health.The podcast also introduces listeners to semagludiet.com, a one-stop resource designed to support people using GLP-1 medications. The site features free tools, meal plans, and the CSS Diet System—an innovative plate and bowl set that promotes portion control while maintaining nutrient density, helping you preserve muscle and bone during weight loss.This conversation also highlights the role of metabolism.com and the Dr. Pepper...Really? podcast in giving voice to medical concerns that often fly under the radar. When public messaging from pharmaceutical companies or regulators fails to capture the full picture, we step in to fill the gap with real talk backed by medical insight.And if you're wondering why you haven't heard this anywhere else, you're not alone. The lack of public awareness may not be accidental—but this podcast isn't about finger-pointing. It's about empowerment through information.Whether you're a healthcare consumer, a concerned friend, or just curious about what's really going on behind the headlines, this episode will change how you view weight loss treatments—and what questions you should be asking next.Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Please consult your personal healthcare provider for diagnosis and treatment decisions.Portions of this episode have been enhanced using artificial intelligence to optimGary Pepper, M.D., an associate professor at a prominent medical school and endocrinologist with 40 years of experience, brings clarity to numerous topics within the field of metabolic health. His view points are unhindered by corporate interests, unlike many other current "thought leaders" in medicine. Dr. Pepper, a dedicated educator, established his homebase website www.metabolism.com in 1996 and has blogged on important topics since then. Not one to be left behind by technology he began podcasting in 2020 with the onset of the pandemic and continues publishing vlogs on YouTube at his channel metabolism123. So whatever your choice in media, you will be gaining fresh insights by tuning in to his opinionated shows or reading his blogs on critical health topics.

Parents don't let your kids out late to shoot others. Trump sending weapons to Ukraine, after days before he said he wouldn't be sending weapons. Rift on the White House? Trump 8-1 SCOTUS win, guess who dissented? Public broadcasting cuts have arrived in Indiana. Honda unplugging SUV EV's. VA cuts coming. The government's role is not to create jobs for people. CVS dropping Zepbound. What will Lilly's response be? Leftist loons compare ICE detention centers to concentration camps. Edgewood High School Sign for your car on the marketplace $800. Time to impeach Justice Jackson. The Trolls are out. Tony tells Tara about them. Death toll in Texas is horrific. Home sellers are quitting the market. Now they are dangling the prosecutions of Comey and Brennan to try and make us forget about Epstein. Trump to tariff imported copper and pharmaceuticals? Caitlin Clark returns to the court today at Noon. Clark sells out seats, not Angel Reese.See omnystudio.com/listener for privacy information.

VA cuts coming. The government's role is not to create jobs for people. CVS dropping Zepbound. What will Lilly's response be? Leftist loons compare ICE detention centers to concentration camps. Edgewood High School Sign for your car on the marketplace $800. Time to impeach Justice JacksonSee omnystudio.com/listener for privacy information.

Ozempic continues to dominate conversations about weight loss, drawing attention from both the medical community and celebrity circles over the past week. This injectable medication, originally designed to manage type two diabetes, has increasingly become known for its ability to help people shed pounds. According to information from Northwestern University published just yesterday, users of Ozempic typically see a gradual but significant reduction in body weight, with clinical trials showing average losses of ten to fifteen percent over the course of a year. For most, the medication begins to make a noticeable difference after about six to eight weeks, particularly when combined with improved diet and regular exercise. However, experts are quick to caution that Ozempic is not a magic solution; sustainable weight loss still relies on lifestyle changes such as healthy eating and physical activity.In the last week, the public conversation around Ozempic has taken on new dimensions. One of the most visible aspects is its popularity among celebrities. According to coverage in the Financial Express from July seventh, high-profile users like Oprah Winfrey, Sharon Osbourne, Whoopi Goldberg, and Rebel Wilson have shared their experiences with Ozempic. Their stories have contributed to the drug's reputation as Hollywood's preferred method for rapid, dramatic weight reduction. However, this visibility has also drawn attention to some unexpected consequences. Dermatologists report an uptick in people experiencing what is now being called Ozempic mouth, a condition marked by significant volume loss and increased wrinkles around the mouth and jawline, which can result in an aged appearance. The rapid loss of facial fat has caused some to seek cosmetic treatments like dermal fillers or skin-tightening procedures to counteract these effects.Oprah Winfrey has been especially vocal and candid about her Ozempic journey in the past week. Reports from Deaconess Health and SheFinds note that Oprah has discussed the medication's role in her recent forty-pound weight loss, which she has attributed to Ozempic, healthy eating, and consistent exercise. During her recent trip to Venice for a celebrity wedding, Winfrey was photographed sporting a noticeably slimmer physique while working out with Gayle King. Fans on social media praised her transformation, and Winfrey herself has emphasized the importance of pairing any medication with dedication to overall well-being. Furthermore, Oprah recently hosted a "State of Weight" panel as part of her ongoing efforts to foster open discussion about weight loss, the struggles involved, and the tools that can help.While Ozempic maintains its position as a popular weight loss solution, new research published in The New England Journal of Medicine and reported by both HealthDay and AOL this week has challenged its supremacy. The study found that another medication, tirzepatide sold under the names Mounjaro and Zepbound, is even more effective at promoting weight loss. Participants taking tirzepatide averaged a twenty percent reduction in body weight, while those on Ozempic averaged about thirteen percent. Experts note that tirzepatide works on two hormone receptors instead of one, which seems to explain its stronger effect. Despite these new findings, Ozempic's influence remains powerful because of its proven track record and cultural prominence.Still, significant safety concerns persist regarding Ozempic's use for weight loss. The Motley Rice law firm and other health sources have reported ongoing lawsuits related to serious side effects, including gastrointestinal issues and, in rare cases, vision loss. Moreover, many patients regain much of the weight they lost if they discontinue the medication, pointing to the need for ongoing management and support rather than quick fixes.In summary, the past week has seen Ozempic's celebrity power and medical potential both celebrated and scrutinized. Oprah Winfrey's openness continues to resonate with many, highlighting that while medications like Ozempic can be helpful tools, the broader journey of weight management demands a holistic approach. The emergence of alternatives such as tirzepatide may shift the landscape, but one message remains clear from experts and high-profile users alike: sustainable weight loss requires lasting lifestyle change, not just a prescription.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why some people seem to drop weight quickly on medications like Wegovy or Zepbound, while others barely budge?The truth is, weight loss isn't as simple as eating less or moving more and even powerful medications don't work the same for everyone. Results often depend on how these drugs are used, the lifestyle habits that support them, and individual factors like metabolism, other health conditions, and how well the body tolerates treatment.That's why it's important to rethink what “success” really means. For many, losing just 5% to 10% of body weight can make a huge difference, improving blood sugar, blood pressure, and cholesterol enough to lower the risk of serious health issues—even if the scale doesn't land exactly where they hoped.In this episode, we'll cover:What success really looks like on Wegovy or ZepboundWhy type 2 diabetes makes weight loss harder, even with GLP-1sHow alcohol use is one of the top reasons people don't see expected resultsThe role of habit snacking and how it can stall progressWhat to do when side effects get in the wayWhen these medications alone aren't enoughAnd what to explore if nothing seems to be workingHit play to find out the top reasons people fall short on Wegovy or Zepbound, how to spot them, and what might finally help you see progress.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.co

Send us a message with this link, we would love to hear from you. Standard message rates may apply.On this episode discuss the side effects of GLP-1 medications like Ozempic and Wegovy, Zepbound, and Mounjaro offering practical strategies to manage these effects while still benefiting from the medications.• GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) help manage type 2 diabetes, obesity, and can reduce cardiovascular risk• Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, bloating, and constipation• "Sulfur burps" are a frequently reported side effect that some manage with Pepto-Bismol• Start with low doses and increase slowly to minimize side effects• Eat smaller portions, avoid greasy/spicy foods, and practice mindful eating to reduce GI symptoms• Stay hydrated and increase fiber intake to prevent constipation• Gallbladder problems and pancreatitis risk may increase with rapid weight loss• Some evidence suggests potential vision changes requiring regular eye check-ups• Medications like insulin or blood pressure drugs may need adjustment when on GLP-1s• Most side effects improve with time as your body adjusts to the medicationSend us an email at yourcheckuppod@gmail.com or visit our Instagram or website to stay updated with weekly episodes released every Monday.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

GLP-1's are tools and if you don't use them well, there's a cost. I'm a registered dietitian, speaker and author who works in the weight loss and GLP-1 space. Here are the 3 most important nutrition pitfalls to avoid if you want to feel your best on a GLP-1 like Ozempic, Mounjaro, Zepbound, & Wegovy.

Is there a better, safer, FREE alternative to Ozempic (and other GLP-1 drugs)? In this episode of Walk, Don't Run to the Doctor, Miles Hassell MD reacts to the growing buzz and shares a time-tested, evidence-based 3-step plan that outperforms popular weight loss drugs in the long run. As GLP-1 drugs like Ozempic, Wegovy, and Mounjaro surge in popularity, Dr. Hassell offers critical insight into their risks—like muscle loss, pancreatic complications, and long-term unknowns—while proposing a practical, natural alternative for lasting weight loss and better metabolic health. Key Takeaways: Why Big Pharma's track record with weight loss drugs demands caution The secret 3-step plan: Eat 6 servings of fruits & veggies, 3 minutes of daily exercise, reduce refined carbs Bonus tips: Bust cravings by eating protein with every meal, daily probiotics, and unlock the power of preemptive eating Why this plan costs nothing, has zero side effects, and starts showing results in just one week A timely message in light of the weight loss drug headlines—who should be in control of your health?  More references can be found at www.GreatMed.org Get your copy of Good Food Great Medicine. https://a.co/d/ajAzYzo Would you like Dr. Hassell to answer your question on the air? Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter. We love to hear from you. This podcast is sponsored by our generous listeners. Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229 References: Chen, X., et al. (2025). Association of dietary fiber intake with all-cause and cardiovascular mortality in diabetes and prediabetes. Diabetology & metabolic syndrome, 17(1), 231. https://pubmed.ncbi.nlm.nih.gov/40533827/   Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism, 27(5), 2720–2729. https://pubmed.ncbi.nlm.nih.gov/39996356/   Wilding, J., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/   Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society, 8(11),https://pubmed.ncbi.nlm.nih.gov/39372917/    Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism, 26 Suppl 4, 16–27. https://pubmed.ncbi.nlm.nih.gov/38937282/   Sato, M., et al. (2023). Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study. Journal of clinical medicine, 12(9), 3104. https://pubmed.ncbi.nlm.nih.gov/37176545/   Monami, M., et al. (2017). Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes, obesity & metabolism, 19(9), 1233–1241. https://pubmed.ncbi.nlm.nih.gov/28244632/   Anderson, S. L., & Trujillo, J. M. (2010). Association of pancreatitis with glucagon-like peptide-1 agonist use. The Annals of pharmacotherapy, 44(5), 904–909. https://pubmed.ncbi.nlm.nih.gov/20371755/   Kapoor, I., Sarvepalli, S. M., D'Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of ophthalmology, 68(6), 1071–1083. https://pubmed.ncbi.nlm.nih.gov/37454782/   Bikou, A., et al. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert opinion on pharmacotherapy, 25(5), 611–619. https://pubmed.ncbi.nlm.nih.gov/38629387/   Jalleh, R. J., et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of clinical endocrinology and metabolism, 110(1), 1–15. https://pubmed.ncbi.nlm.nih.gov/39418085/   Berg, S. AMA. (2023). Questions patients may have about weight-loss drugs. https://www.ama-assn.org/delivering-care/public-health/questions-patients-may-have-about-weight-loss-drugs   Friedman, J. (2025). America's up-and-down history with weight-loss drugs. https://www.history.com/articles/weight-loss-drugs-america    

Let's be honest, everyone's talking about GLP-1s (Ozempic, Wegovy, Zepbound), but no one's telling the whole story. Until now.This week, we're joined by the brilliant Dr. Alexandra Sowa—board-certified physician, NYU clinical instructor, founder of SoWell, and author of The Ozempic Revolution—for the ultimate deep dive into everything you actually need to know about navigating life on (and off) GLP-1s. From weight loss plateaus and blood sugar crashes to the infamous “Ozempic face,” nothing is off-limits. We break down the stigma, the science, and why it's not about getting thin—it's about getting healthy. We also unpack the tests your doctor probably isn't running (but should), the supplements that can make or break your progress, and why most people are doing GLP-1s totally wrong. Whether you're curious, committed, or just confused, this episode is your go-to guide to understanding your metabolism, hormones, and long-term health—without shame and without shortcuts. Mentioned in the Episode: SoWell GLP-1 Support System  The Ozempic Revolution by Dr. Alexandra Sowa HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) Calculator GLP-1 Medication Insurance Toolkit Your Friends & Neighbors (Apple TV) SoWell Electrolytes A Sony Music Entertainment production.  Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts  To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________Dr. David Kessler, former FDA Commissioner and author of Diet, Drugs, and Dopamine, joins us to break down the science behind food addiction, obesity, and GLP-1 medications like Ozempic and Zepbound.He doesn't just study this—he lives it. Dr. Kessler has obesity, takes GLP-1s, and knows firsthand what it's like to battle food noise and weight stigma.In this episode, we discuss:What makes ultra-processed food addictiveHow GLP-1s affect the brain and reduce cravingsWhether some people can stop taking GLP-1sHis personal experience starting, stopping, and restartingWhy weight regain happens and what the body is really fightingHis bold policy ideas to regulate Big Food like Big TobaccoDr. Kessler helped bring HIV drugs to market faster, led Operation Warp Speed, and took on the tobacco industry. Now, he's focused on the next public health crisis: food addiction and obesity.Subscribe to The Plus SideZ Podcast for more expert conversations on GLP-1s, weight, and wellness.Specialist and Community Guest Dr. David KesslerBIO: David. A. Kessler, MD, served as chief science officer of the WhiteHouse COVID-19 Response Team under President Joe Biden and previouslyserved as commissioner of the US Food and Drug Administration underPresidents George H.W. Bush and Bill Clinton. He is the author of the_New York Times_ bestsellers _The End of Overeating_ and_ Capture_ andtwo other books:_ Fast Carbs, Slow Carbs_ and _A Question of Intent_.Dr. Kessler is a pediatrician and has been the dean of the medicalschools at Yale and the University of California, San Francisco. He is agraduate of Amherst College, the University of Chicago Law School, andHarvard Medical School.Social Media:https://x.com/DavidAKesslerMDLink to Book:https://www.audible.com/pd/B0D5KS9P4D?source_code=ASSORAP0511160006&share_location=pdpSpecial community guest Mike on a Health Mission Social MedSend us Fan Mail! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #insurance #cvscaremark

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today we're diving into a topic that's been everywhere lately: GLP-1 medications like semaglutide and tirzepatide for weight loss. You may know them by names like Wegovy, Ozempic, Mounjaro, or Zepbound. I want to give you a clear, realistic picture of what to expect—because while the media loves to highlight the dramatic before-and-after photos, the real journey can be slower and more nuanced for some. So in this episode, we're going to talk about the truth—what these medications can do, what they can't, how long things really take, and what you need to know to set yourself up for success. Not hype, not magic promises—just real, honest insight to help you understand the process. Let's get into it. How GLP-1 & GIP/GLP-1 Agonists Work So first things first—how do these meds work? Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist. Basically, they mimic natural hormones in your body that help regulate blood sugar, slow digestion, and—most importantly for weight loss—reduce appetite and improve satiety. That means you feel fuller faster and stay full longer. You're not obsessing over food like before. And that's powerful. But—and this is a big one— these peptides don't magically erase years of weight gain overnight. What they do is help make weight loss easier by reducing hunger and supporting your metabolism—but they don't do all the work for you. It's important to remember they're a powerful tool, not a replacement for your efforts. You're still in control of your choices, habits, and long-term success. Why We Titrate the Dose—and What "Therapeutic Dose" Means Now, let's talk about dosing. When you start Wegovy, you don't start at the highest dose. It's gradually increased over several weeks to give your body time to adjust and to help reduce side effects like nausea or stomach upset. The usual schedule looks like this: You'll start with 0.25 mg once a week for the first month. Then it increases every four weeks—0.5 mg, then 1 mg, then 1.7 mg. By week 17, most people reach the full dose of 2.4 mg once a week—that's the dose shown in studies to lead to the most consistent weight loss, with many people losing around 15% of their total body weight over about a year. But here's the thing—not everyone follows this path exactly, and that's okay. Some people need to slow down or stay longer at a lower dose if they're having side effects. Others may need to increase sooner if they're not seeing appetite changes and are tolerating the medication well. And even though 2.4 mg is considered the “therapeutic dose,” not everyone needs to reach it. Some people feel great and lose weight at a lower dose—and if that's you, that's your sweet spot. The real goal is to find the lowest effective dose that controls your hunger, helps you lose weight at a steady pace, and keeps side effects to a minimum. This isn't a one-size-fits-all journey, and pushing through side effects just to hit the max dose isn't necessary—or safe. Your best dose is the one your body handles well and helps you make progress. *How Much Weight Can You Expect to Lose—and How Fast? Let's take a look at the clinical studies. In large trials, people on semaglutide lost about 15% of their total body weight over 68 weeks. For tirzepatide, it was even higher—20% or more in some cases. But here's the thing—those results happened over a year to a year and a half. Not 6 weeks. Not 3 months. It's a marathon, not a sprint. Also, most of the weight loss doesn't happen during the titration phase. You may see some weight loss early on, especially if your appetite plummets. But the bulk of the weight loss happens once you reach and maintain your therapeutic dose. Why Everyone's Journey Looks Different I can't stress this enough—everybody's journey is different. Some people feel zero hunger from their very first injection. Others don't notice a big change until week 10 or 12. Some drop 10 pounds in the first month. Others lose two pounds and feel discouraged. All of those experiences are normal. Your age, hormones, medications, stress levels, sleep, and past diet history? They all play a role. And let's be real—gaining 20, 50, or 100 pounds didn't happen in a few weeks, right? It likely took months or even years of lifestyle habits, hormonal shifts, emotional eating, or underlying conditions. So we have to give ourselves that same grace and patience when we're trying to take the weight off—even with medical support. Navigating Side Effects and Setbacks Let's talk about the side effects. Nausea, constipation, acid reflux, bloating—yeah, these are pretty common as your body adjusts. And sometimes, those symptoms are your body's way of saying: Hey, slow down. Pushing through intense side effects just to hit a higher dose isn't the goal. In fact, it's not safe. You want the lowest effective dose that keeps your appetite under control, the weight coming off gradually, and your side effects minimal or nonexistent. If you need to pause treatment to let your gut settle or even go back down a dose, that's not failure. That's smart, safe self-care. We're in this for the long haul. Trial and Error with Food—and That's OK One part of this journey that catches people off guard is how sensitive your stomach becomes—especially to certain foods or drinks. Greasy or fried foods, spicy meals, carbonated drinks, alcohol—these can all be triggers for nausea or even vomiting while you're on this medication.  And it makes sense when you think about it: the medication slows down how quickly food and drink leave your stomach. So if you're eating or drinking things that already tend to irritate the stomach lining, the effects can hit harder and last longer. Even if those foods didn't bother you before starting treatment, they might now. It's just one of those things your body has to adjust to, and it may take some trial and error to figure out what still works for you. What is Healthy, Sustainable Weight Loss? So what's a healthy pace of weight loss? In general, 1 to 2 pounds per week is considered safe and sustainable. But on GLP-1s, that might vary. Some weeks you may lose 3 pounds. Some weeks, nothing. And guess what? That's normal. You're looking for overall downward trends, not perfection. The goal here is steady, sustainable fat loss—not dropping weight so quickly that you feel miserable, drained, or start losing muscle. Remember, we're not chasing “skinny”—we're aiming for strong, lean, energized, and healthy. And I know we've talked about this before, but it's worth repeating: exercise is not optional when you're on a GLP-1. It's a must. When you lose weight, you lose both fat and muscle. If you're not actively working to maintain or build muscle, you risk becoming weaker and slowing down your metabolism in the process. We want to keep the muscle you have—and ideally, build more—so your body stays strong and your results last. What Is a “Non-Responder”? Now let's touch on something important: what if the medication doesn't seem to work? Let's talk about what it means to be a “non-responder” on a GLP-1 medication like Wegovy or Zepbound. In clinical terms, a non-responder is someone who has been on their therapeutic dose for at least 3 months and has lost less than 5% of their total body weight—even though they're taking the medication correctly and making lifestyle changes like adjusting their diet, increasing physical activity, and managing stress or sleep. Let's break that down with an example: If someone weighs 200 pounds, 5% of their total body weight would be 10 pounds. So if they've been on their therapeutic dose for 12 weeks and have only lost, say, 4 or 5 pounds—despite doing everything right—they may be considered a non-responder. But as we mentioned before, everyone's therapeutic dose may be different. The therapeutic dose isn't just the maximum dose like 2.4 mg of semaglutide or 15 mg of tirzepatide. It's the dose at which you personally begin to experience consistent appetite suppression, weight loss, and minimal side effects. For some people, that may happen at 1 mg of semaglutide. Others may not feel much of a difference until they reach the full 2.4 mg. Some may even respond better at 1.7 mg and not tolerate the higher dose at all. That's why we titrate slowly, monitor your symptoms, and assess both how you feel and how your body is responding. So how do we know if you've reached your therapeutic dose? We look at things like: Has your appetite significantly decreased? Are you noticing earlier fullness or fewer cravings? Are you losing weight consistently over time Are side effects tolerable or nonexistent? If the answer is yes, you're probably at your therapeutic dose. But if the answer is no—if your hunger hasn't changed much, the scale hasn't moved, and you're not noticing any shift in your eating patterns after 3 months on a stable, higher dose—it might be time to re-evaluate. That could mean adjusting the dose, checking for other health issues that might be interfering (like thyroid problems or certain medications), or even considering a different treatment approach. *So what are my final thoughts?  Your journey is unique. Not everyone responds the same way, and that's okay. The key is finding what works for your body, not just what the label says. These medications can absolutely change lives. But they're not magic. They work with your efforts—not instead of them. You'll need to be patient, flexible, and kind to yourself along the way. You may need to tweak your dose, change your food choices, or give your body time to adjust. That's part of the process. And remember—this isn't just about weight loss. It's about reclaiming your health, confidence, and energy. So take it one step at a time. Celebrate every win. And know that slow progress is still progress. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, be patient, and keep showing up for yourself. And as always, have a happy, healthy week.

Listen in as Joseph Kim, MD, MPH, MBA; Manish Shah, MD; Martha Grugel, MA, discuss how they manage the prior authorization process for antiobesity agents to improve the quality of their care delivery, including:The information to collect during patient visitsThe available resources to help you submit prior authorizationsThe supporting documents that are often necessary to accompany prior authorizationsHow to address denials and appealsWhen to access manufacturer-based or foundation-based financial assistancePresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaManish Shah, MDClinical Associate Faculty MS1 PreceptorUniversity of Florida College of MedicineGainesville, FloridaMartha Grugel, MAMedical AssistantWesley Chapel, FloridaLink to full program: https://bit.ly/45P0v8z

Weight loss drugs are everywhere and recently Zepbound (tirzepitide) made big news when it became the first FDA-approved sleep apnea therapy for mild to moderate sleep apnea. In this episode, we will:Introduce and explain weight loss medicationsReview the studies that convinced the FDA to approve Zepbound for sleep apneaProvide an overview on this class of weight loss medicationsEvaluate the risks and determine who is a best match for this therapyTouch on the cost and difficulty in getting these drugs approvedRevisit Apnimed's SynAIRgy press release and how it relates to our discussion in episode 110 of the podcastProduced by: Maeve WinterMore Twitter: @drchriswinter IG: @drchriwinter Threads: @drchriswinter Bluesky: @drchriswinter The Sleep Solution and The Rested Child Thanks for listening and sleep well!

What if your best body, clearest mind, and strongest sense of purpose were still ahead of you? That's the question I explore in this episode with Richard Rosenfeld, MD, MPH, MBA. He's a board-certified ENT, Director of Guidelines and Quality at the American College of Lifestyle Medicine, and one of the most published ENT researchers in the world—with nearly 400 peer-reviewed articles to his name. But what really sets Rich apart is his personal story. In his mid-50s, he hit a turning point—and decided to change course. He adopted a whole food, plant-based lifestyle. Picked up strength training again after decades off. Started running. Now, in his 60s, he's finished 10 marathons, lifts consistently, and says he feels sharper and more alive than ever. In This Episode, We Dive Into: What sparked Rich's midlife transformation How he fuels, trains, and recovers today Strength training after 50 and the role of protein and creatine His honest take on GLP-1 meds (like Wegovy and Zepbound) for weight loss And how mindset, curiosity, and purpose fuel long-term change We also talk about the culture of medicine—and what it'll take to build a system that actually supports health, not just disease management. This conversation is full of science-backed insight and lived experience. And it's a story that reminds you what's possible—no matter your starting point. Live well and RAK ON, Dr. Rak

Welcome back to Diamond Paint and Podcast — where I ramble, reflect, and real-talk my way through a diamond painting session.In this episode, we're all over the place in the best way possible. I'm chatting about:The “Donut Mom” at cheerleading

In this Trending Health series, Vynamic team members will highlight how different sectors of the health industry are evolving to meet the demands of today's ever-changing healthcare landscape through value creation and strategic transformations.In this episode, Mindy McGrath, Saurabh Raman, and Ryan Hummel dive into how payers are shifting from short-term cost cutting to long-term strategic transformation as a result of rising costs, policy upheaval, and evolving consumer demands.To learn more about how we can help your team navigate these strategic decisions, reach out to Saurabh.Raman@vynamic.com and Ryan.Hummel@vynamic.com. Podcast Tags: healthcare, health plan, healthcare strategy, health innovation, strategic transformation Source Links:Medical cost trend: Behind the numbers 2025 UnitedHealth reports highest medical costs since COVID-19 pandemic's start New Evernorth program to cap out-of-pocket costs for Wegovy, Zepbound at $200 Spending growth on GLP-1s outpaces specialty drugs: Evernorth study Elevance Health Reports First Quarter 2024 Results Panel – Mindy McGrath, Saurabh Raman, Ryan Hummel Research & Production – Julia Morrison, Saurabh Raman, Ryan Hummel, Everly PetruzzelliRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com. 

Americans are unusually overweight and chronically ill compared to similarly rich countries. This episode presents a grand, unified theory for why that's the case. Our food environment has become significantly more calorie-rich and industrialized in the past few decades, sending our obesity rates soaring, our visceral fat levels rising, and our chronic inflammation surging. The result is an astonishing rise in chronic illness in America. That's the bad news. The good news is that GLP-1 drugs, like Ozempic and Zepbound, seem to be astonishingly successful at reversing many of these trends. This episode blends two interviews with Dr. David Kessler and Dr. Eric Topol. Kessler was the commissioner of the Food and Drug Administration under the Bush and Clinton administrations, from 1990 to 1997. He helped lead Operation Warp Speed in its final months. He is the author of the book 'Diet, Drugs, and Dopamine.' Topol is a cardiologist and the founder and director of the Scripps Research Translational Institute. He is the author of the book 'Super Agers.' If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: Dr. David Kessler and Dr. Eric Topol Producer: Devon Baroldi Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's only June. That means you still have six full months to change your life. Seriously. Who do you want to be when the ball drops on December 31st?Are you going to be crying in the bathroom again because nothing fits? Googling “how to lose weight fast” for the hundredth time? Or are you going to feel proud as hell that you didn't give up on yourself this time?In this episode, I'm talking about what's actually possible in six months and how showing up with consistency (not perfection!) can transform how you feel, how you live, and how you see yourself.If you're tired of starting over every Monday, hating your life, emotionally eating your days away, and waiting for “the right time,” this is your wake-up call.Let's talk about who you could be by the end of the year and how to start becoming her now.

SUPPORT OUR WORK AND GET MORE NEWS! https://linktr.ee/manonthemounjaro

 We know GLP-1 meds are still a hot topic, so wanted to share our journey with you all. We both came to the decision to start taking Zepbound after coming off Mounjaro in 2023. Tune in and listen to why we chose to start Zepbound, what method we are using and what we hope to achieve. In this episode, we also discuss what we learned from Mounjaro just a few years ago to help us prepare for part 2 of this journey. We both spoke to our doctors and explained what we were hoping to achieve and they were both on board. We are THRILLED that medical professionals are willing to help fight this disease of obesity, no matter what it takes! And we are both fortunate enough to have those caring and invested doctors to aid us in this journey. Both doctors covered with us how to properly pull the injection and how to administer it. Explained possible side effects, talked about diet and exercise in a caring and helpful manner. All the things that we deserve as humans in this battle for health! Our advice? If your doctor isn't willing to walk the path with you... FIND A NEW DOCTOR! Like now! The only missing puzzle piece here is to get the insurance companies up to speed. Neither of our insurance companies will cover the drug. So, we had to seek alternate routes to make it affordable. Tune in if you're curious to hear more about that, as we explain it in detail in this episode. We are excited to kick off this new journey and we're looking forward to taking you along for the ride! Follow Justy & Steph on Instagram, where they share their weight loss journey and road to living a happy & healthy lifestyle.@we.are.losing.it If you prefer video to see us talk through our topics, you can watch us on YouTube. https://youtube.com/@wearelosingitShow your support by hitting download, like & subscribe! We truly appreciate each and every one of you!!

Ian Bremmer, president of the Eurasia Group, joins "CBS Mornings" to break down a weekend of deep division in the U.S., as millions protested President Trump and his military parade, and deadly new strikes between Iran and Israel raised fears of a wider regional war in the Middle East. The jury in Karen Read's retrial began deliberations Friday afternoon and will continue Monday. Read is facing three charges in the 2022 death of her police officer boyfriend, John O'Keefe, including second-degree murder. Her first trial ended with a hung jury. Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' Nancy Chen reports on the qualifications for the discount and what the cost reduction will be. Artificial intelligence is being used to create realistic video and audio to impersonate people, in some cases looking for love or deceiving companies looking to hire. In a 2024 study, half of the businesses surveyed said they'd experienced AI deepfake fraud. CBS News MoneyWatch correspondent Kelly O'Grady reports. In this week's "Beg-Knows America," CBS News contributor David Begnaud revisits the life-changing world of high school speech and debate, an activity that shaped his own path. He meets the inspiring young voices featured in the new documentary "SPEAK," tackling grief, identity, and advocacy with extraordinary courage. Consumer Reports' deputy editor Brian Vines joins "CBS Mornings" to share the latest sunscreen testing results, including top-rated picks and expert tips to keep you and your family safe in the sun this summer. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Welcome to the first episode of Diamond Paint and Podcast — a cozy space where I decompress, diamond paint, and talk through the emotional weight of everyday life.This series is for those of us who are just trying to feel like ourselves again one tiny sparkle at a time. No filters, no scripts, no pressure. Just real talk while I work on something that feeds my soul.In this first episode, I'm catching you up on life lately, how I've been feeling, and where my head's been. It's not polished. It's not planned. It's just me decompressing, rambling, and trying to process the chaos with a side of bling!

Listen in as Joseph Kim, MD, MPH, MBA, interviews Natalie, Orbach, PA-C, to learn about how she implemented patient-centered and individualized treatment plans to improve obesity care at her practice, includingDiscussing weight and how nutrition, physical activity, mental health, and pharmacotherapy strategies can helpMeeting patients where they are at and offering slow, incremental changes that support long-term outcomesReferring patients to community resources and other professionals as needSharing lessons learned for those interested in implementing similar strategies in their practice PresenterJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaNatalie Orbach, PA-CPhysician AssistantFeirtag & Ramos, PALutherville, Maryland Link to full program: https://bit.ly/45P0v8z

More and more people with type 1 are using GLP-1 receptor agonists. You know these medications, with brand names like Ozempic, Mounjaro, Wegovy and Zepbound, but none of them are specifically approved to treat T1D. Some of the first studies are underway to study the safety and effectiveness of GLP-1s, but that hasn't stopped thousands of using them off-label or to treat obesity. We're talking to an endocrinologist and a clinical pharmacist about why they prescribe these meds to some of their type 1 patients, who they won't prescribe them for, and – I know you're already asking – how they get insurance coverage.   My guests are endocrinologist Dr. Adam Spitz and Clinical Pharmacist Georgina Farrow GLP news story Stacey references here Dr Spitz's medical thriller here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

You ever lie in bed at night, thinking about all the things you're going to do tomorrow, like wake up early, eat better, clean the house, work out, be more present, but then tomorrow comes… and you're right back in survival mode? Girl, I get it! Please hear this: you're not lazy - you're at maximum capacity. In this episode, I'm getting real about the exhaustion of good intentions that never get met, the emotional weight of feeling stuck, and the shame that sneaks in when you know you're capable of more but can't seem to show up. If you're just getting by and tired of feeling like you're failing… this one's for you.

Did you know a daily weight loss pill might soon replace weekly injections for managing obesity? In this episode, I explore the exciting new development of a once-daily oral weight loss medication, oral semaglutide 50mg highlighting results from the OASIS 1 trial. With this, I explain how this pill could be a game-changer for people who are hesitant about injections like Wegovy or Zepbound. I break down how semaglutide works as a GLP-1 receptor agonist, the phases of drug development, and the impressive trial results showing an average 15% body weight loss in participants without diabetes. I also talk about common side effects, the FDA approval timeline, and what this could mean for patients looking for more accessible, convenient weight loss options. Curious about the future of weight loss treatments? Tune in to learn about a groundbreaking pill that could change everything.   Episode Highlight: Introduction of oral semaglutide 50mg as a potential weight loss pill  Explanation of how semaglutide works as a GLP-1 receptor agonist. Overview of the OASIS 1 phase 3 trial Breakdown of clinical trial phases and FDA approval process. Discussion of side effects Adherence rates and significant weight loss among participants. Insight into future FDA approval timelines and potential market release Importance of combining medication with lifestyle changes Considerations about insurance coverage and patient access   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH. Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014. In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss, where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this powerful and unapologetic episode, I sit down with Dr. Tyna Moore — physician, author, and outspoken advocate for evidence-based metabolic health — for a deeply candid conversation about peptides, GLP-1s (like Ozempic, Mounjaro, Wegovy, and Zepbound), and why the current medical system is failing women. We dive into:

Episode 2647: Vinnie Tortorich and Chris Shaffer discuss traveling, going down a bad road with GLP-1s and muscle loss, and more. https:vinnietortorich.com/2025/05/going-down-a-bad-road-episode-2647 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Going Down A Bad Road Vinnie is traveling soon and is looking forward to going back home for crawfish season. (2:30) A good road trip is a nice “mental massage.” (5:15) He shares what he packs for the road trip. All of Vinnie's businesses will be consolidated into one website soon. (16:00) Pure Vitamin Club, Pure Coffee Club, and NSNG Foods will be available on one website. Chris brings up Good Morning America and GLP-1s. (18:00) Zepbound is being touted as the most effective, but, of course, it will come at a cost. The drastic loss of muscle is a concern; after all, your heart is a muscle! Ten percent (the low-end percentage) of muscle loss in the 60 to 72 week time span is the same as 20 yearsof sarcopenia. (25:00) They give an example of a VIP member who has been slow to lose weight; however, they have figured out this person is undereating! Your metabolism can slow down if you aren't getting enough calories. It can be as simple as adding another egg or two to make sure you are getting enough. This is the challenge with intermittent fasting and OMAD (one meal a day) approaches to eating. If you allow yourself to eat a treat, just get right back on the NSNG® plan. If you aren't sure how to get started with NSNG®, get Vinnie's e-book.  Chris shares some of his weight loss journey.  (42:00) He discovered his wheat and gluten sensitivity after stopping eating certain foods like pizza and pasta. Now he is so well-tuned with his health, he can tell if even a small amount of wheat is in his food. Avoid processed foods; they are addictive and damaging to your health. More News If you are interested in the NSNG® VIP group is currently closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: